GILD vs REGN
Gilead Sciences (GILD) and Regeneron Pharmaceuticals (REGN) compared side by side. Gilead Sciences (GILD) is larger, with a market cap of $193.5B versus $82.9B for Regeneron Pharmaceuticals, about 2.3 times the size. REGN returned +40.6% over the past year including dividends, versus +32.4% for GILD, through October 23, 2026..
Head to head
| Metric | GILD | REGN |
|---|---|---|
| Market cap | $193.5B | $82.9B |
| P/E (TTM) | — | 19.9x |
| Forward P/E | 15.6x | 12.8x |
| Revenue (TTM) | $30.5B | $15.5B |
| Revenue growth | 10.2% | 16.7% |
| Gross margin | 79.6% | 44.5% |
| Operating margin | 33.7% | 33.1% |
| Free cash flow | $12.9B | $3.6B |
| Dividend yield | 2.10% | 0.47% |
| 1-year return | +32.4% | +40.6% |
| 5-year return (annual) | +22.6% | +7.3% |
| Max drawdown | -71% | -92% |
| FI Handbook grade | B- | B+ |
Highlighted: the stronger figure on metrics where higher or lower is clearly better.
Growth of $10,000 (5 years, price only)
GILD vs REGN FAQ
Which is bigger, GILD or REGN?
Gilead Sciences (GILD) is larger, with a market cap of $193.5B versus $82.9B for Regeneron Pharmaceuticals, about 2.3 times the size.
Which stock performed better over the past year, GILD or REGN?
REGN returned +40.6% over the past year including dividends, versus +32.4% for GILD, through October 23, 2026.
Which pays a higher dividend, GILD or REGN?
GILD yields 2.10% versus 0.47% for REGN.
Full pages: Gilead Sciences · Regeneron Pharmaceuticals